JP2019524710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524710A5 JP2019524710A5 JP2019500453A JP2019500453A JP2019524710A5 JP 2019524710 A5 JP2019524710 A5 JP 2019524710A5 JP 2019500453 A JP2019500453 A JP 2019500453A JP 2019500453 A JP2019500453 A JP 2019500453A JP 2019524710 A5 JP2019524710 A5 JP 2019524710A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pulmonary
- compound
- crystalline free
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 86
- 238000001228 spectrum Methods 0.000 claims description 62
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 61
- 201000010099 disease Diseases 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 42
- 239000002002 slurry Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 20
- 230000002685 pulmonary effect Effects 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000002329 infrared spectrum Methods 0.000 claims description 18
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
- 201000006370 kidney failure Diseases 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 208000017169 kidney disease Diseases 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 210000002216 heart Anatomy 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 208000007056 sickle cell anemia Diseases 0.000 claims description 9
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 8
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 8
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 8
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 8
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 8
- 201000011461 pre-eclampsia Diseases 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
- 208000006029 Cardiomegaly Diseases 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 6
- 208000033626 Renal failure acute Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 201000000306 sarcoidosis Diseases 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 238000005079 FT-Raman Methods 0.000 claims description 5
- 230000001746 atrial effect Effects 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 230000001568 sexual effect Effects 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 206010003671 Atrioventricular Block Diseases 0.000 claims description 4
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 206010006482 Bronchospasm Diseases 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010027525 Microalbuminuria Diseases 0.000 claims description 4
- 208000034486 Multi-organ failure Diseases 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- 206010063985 Phytosterolaemia Diseases 0.000 claims description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 4
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- 208000003782 Raynaud disease Diseases 0.000 claims description 4
- 208000002227 Sitosterolemia Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000035508 accumulation Effects 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 206010002906 aortic stenosis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000007885 bronchoconstriction Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229940109239 creatinine Drugs 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 230000003205 diastolic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000036244 malformation Effects 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 208000007232 portal hypertension Diseases 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 210000001147 pulmonary artery Anatomy 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000002861 ventricular Effects 0.000 claims description 4
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000001231 mediastinitis Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 3
- 201000004409 schistosomiasis Diseases 0.000 claims description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010001580 Albuminuria Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010002915 Aortic valve incompetence Diseases 0.000 claims description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 2
- 206010003175 Arterial spasm Diseases 0.000 claims description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 208000002102 Atrial Premature Complexes Diseases 0.000 claims description 2
- 206010003662 Atrial flutter Diseases 0.000 claims description 2
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 claims description 2
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 2
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims description 2
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims description 2
- 206010053567 Coagulopathies Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000019886 Congenital renal disease Diseases 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012305 Demyelination Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000004483 Dyspareunia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000007530 Essential hypertension Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 206010070538 Gestational hypertension Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020802 Hypertensive crisis Diseases 0.000 claims description 2
- 206010020852 Hypertonia Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010058558 Hypoperfusion Diseases 0.000 claims description 2
- 206010021133 Hypoventilation Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- -1 IPAC Chemical compound 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 206010025219 Lymphangioma Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000020128 Mitral stenosis Diseases 0.000 claims description 2
- 208000011682 Mitral valve disease Diseases 0.000 claims description 2
- 206010027727 Mitral valve incompetence Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010061533 Myotonia Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 206010034487 Pericarditis constrictive Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 206010061340 Peripheral embolism Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims description 2
- 201000001068 Prinzmetal angina Diseases 0.000 claims description 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims description 2
- 206010068690 Pulmonary vein occlusion Diseases 0.000 claims description 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 201000007981 Reye syndrome Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- 201000004239 Secondary hypertension Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 208000007718 Stable Angina Diseases 0.000 claims description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims description 2
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 claims description 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims description 2
- 208000001163 Tangier disease Diseases 0.000 claims description 2
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 2
- 231100000076 Toxic encephalopathy Toxicity 0.000 claims description 2
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 claims description 2
- 206010044640 Tricuspid valve incompetence Diseases 0.000 claims description 2
- 206010044642 Tricuspid valve stenosis Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 208000012931 Urologic disease Diseases 0.000 claims description 2
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims description 2
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 208000008131 Ventricular Flutter Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims description 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 2
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 208000013228 adenopathy Diseases 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 201000002064 aortic valve insufficiency Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 208000037849 arterial hypertension Diseases 0.000 claims description 2
- 210000002565 arteriole Anatomy 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 230000004097 bone metabolism Effects 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 2
- 206010007625 cardiogenic shock Diseases 0.000 claims description 2
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000003788 cerebral perfusion Effects 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 208000028831 congenital heart disease Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 208000000839 constrictive pericarditis Diseases 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 210000001652 frontal lobe Anatomy 0.000 claims description 2
- 230000001434 glomerular Effects 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 2
- 201000005991 hyperphosphatemia Diseases 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 208000018875 hypoxemia Diseases 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 230000028252 learning or memory Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 201000002818 limb ischemia Diseases 0.000 claims description 2
- 230000006372 lipid accumulation Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 208000006887 mitral valve stenosis Diseases 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 230000004112 neuroprotection Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 208000021090 palsy Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000008447 perception Effects 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims description 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 230000036316 preload Effects 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 208000037920 primary disease Diseases 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 208000009138 pulmonary valve stenosis Diseases 0.000 claims description 2
- 210000003492 pulmonary vein Anatomy 0.000 claims description 2
- 208000030390 pulmonic stenosis Diseases 0.000 claims description 2
- 230000010451 regulation of platelet aggregation Effects 0.000 claims description 2
- 208000015658 resistant hypertension Diseases 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 230000000542 thalamic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000009424 thromboembolic effect Effects 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 206010046459 urethral obstruction Diseases 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
- 238000001237 Raman spectrum Methods 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 230000001351 cycling effect Effects 0.000 claims 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 description 11
- 230000004761 fibrosis Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 201000002793 renal fibrosis Diseases 0.000 description 5
- 206010011878 Deafness Diseases 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 208000016354 hearing loss disease Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 201000009925 nephrosclerosis Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000000185 Localized scleroderma Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010067092 AIDS cholangiopathy Diseases 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000024815 Granulomatous liver disease Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022107994A JP2022130689A (ja) | 2016-07-07 | 2022-07-04 | Ｓｇｃ刺激剤の固体形態 |
| JP2025075532A JP2025118738A (ja) | 2016-07-07 | 2025-04-30 | Ｓｇｃ刺激剤の固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359466P | 2016-07-07 | 2016-07-07 | |
| US62/359,466 | 2016-07-07 | ||
| PCT/US2017/040827 WO2018009609A1 (en) | 2016-07-07 | 2017-07-06 | Solid forms of an sgc stimulator |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107994A Division JP2022130689A (ja) | 2016-07-07 | 2022-07-04 | Ｓｇｃ刺激剤の固体形態 |
| JP2025075532A Division JP2025118738A (ja) | 2016-07-07 | 2025-04-30 | Ｓｇｃ刺激剤の固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524710A JP2019524710A (ja) | 2019-09-05 |
| JP2019524710A5 true JP2019524710A5 (OSRAM) | 2020-08-20 |
Family
ID=59337923
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500453A Pending JP2019524710A (ja) | 2016-07-07 | 2017-07-06 | Ｓｇｃ刺激剤の固体形態 |
| JP2022107994A Pending JP2022130689A (ja) | 2016-07-07 | 2022-07-04 | Ｓｇｃ刺激剤の固体形態 |
| JP2025075532A Pending JP2025118738A (ja) | 2016-07-07 | 2025-04-30 | Ｓｇｃ刺激剤の固体形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107994A Pending JP2022130689A (ja) | 2016-07-07 | 2022-07-04 | Ｓｇｃ刺激剤の固体形態 |
| JP2025075532A Pending JP2025118738A (ja) | 2016-07-07 | 2025-04-30 | Ｓｇｃ刺激剤の固体形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US10889577B2 (OSRAM) |
| EP (1) | EP3481820B1 (OSRAM) |
| JP (3) | JP2019524710A (OSRAM) |
| KR (2) | KR102803160B1 (OSRAM) |
| CN (1) | CN109563087A (OSRAM) |
| AU (1) | AU2017292818B2 (OSRAM) |
| BR (1) | BR112019000293A2 (OSRAM) |
| CL (1) | CL2019000018A1 (OSRAM) |
| EA (1) | EA039753B1 (OSRAM) |
| IL (1) | IL263996B2 (OSRAM) |
| JO (1) | JOP20180127A1 (OSRAM) |
| MA (1) | MA45588A (OSRAM) |
| MX (2) | MX389964B (OSRAM) |
| TW (1) | TWI774683B (OSRAM) |
| WO (1) | WO2018009609A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102803160B1 (ko) | 2016-07-07 | 2025-04-30 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 고체 형태 |
| CA3029375A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Novel processes for preparation of soluble guanylate cyclase stimulators |
| SG10202100168XA (en) | 2016-07-07 | 2021-02-25 | Cyclerion Therapeutics Inc | Novel processes for preparation of soluble guanylate cyclase stimulators |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| CN109503574B (zh) * | 2018-12-14 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 抗肺动脉高压药物sgc-003的多晶型晶体变体及其制备方法 |
| CN110862424A (zh) * | 2019-12-03 | 2020-03-06 | 海南顿斯医药科技有限公司 | 一种硫酸阿米卡星化合物 |
| WO2023009710A1 (en) * | 2021-07-28 | 2023-02-02 | Cyclerion Therapeutics, Inc. | Treatment of hfpef in post-menopausal women with an sgc stimulator |
| CN114199812A (zh) * | 2021-12-28 | 2022-03-18 | 南通联亚药业有限公司 | 一种盐酸美金刚缓释制剂中盐酸美金刚的检测方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| EP0605622B1 (en) | 1991-09-24 | 1997-11-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| ES2157254T3 (es) * | 1993-03-12 | 2001-08-16 | Upjohn Co | Ceftiofur (acido libre) cristalino. |
| US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| NZ310559A (en) | 1995-06-21 | 1999-05-28 | Shionogi & Co | Bicyclic sulphonamide and carboxamide derivatives and medicaments |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| JP4120993B2 (ja) | 1996-12-12 | 2008-07-16 | 塩野義製薬株式会社 | ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤 |
| BR9714016A (pt) | 1996-12-13 | 2000-02-29 | Shionogi & Co | Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| ATE311200T1 (de) | 2000-04-12 | 2005-12-15 | Merck Frosst Canada Inc | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| AR035431A1 (es) | 2001-02-13 | 2004-05-26 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| KR20040044856A (ko) | 2001-09-07 | 2004-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체 화합물 |
| JP2005508321A (ja) * | 2001-09-26 | 2005-03-31 | メルク エンド カムパニー インコーポレーテッド | 結晶形態のエルタペネムナトリウム |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
| WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| MA34330B1 (fr) | 2010-05-27 | 2013-06-01 | Merck Sharp & Dohme | Activateurs de guanylate cyclase soluble |
| US8748442B2 (en) | 2010-06-30 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| RU2582679C2 (ru) * | 2010-11-09 | 2016-04-27 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
| CA2907111C (en) * | 2013-03-15 | 2023-10-24 | Joel Moore | Sgc stimulators |
| EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| JP6624616B2 (ja) * | 2014-09-17 | 2019-12-25 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激剤 |
| KR102803160B1 (ko) * | 2016-07-07 | 2025-04-30 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 고체 형태 |
-
2017
- 2017-07-06 KR KR1020237017060A patent/KR102803160B1/ko active Active
- 2017-07-06 EA EA201990235A patent/EA039753B1/ru unknown
- 2017-07-06 US US16/315,226 patent/US10889577B2/en active Active
- 2017-07-06 EP EP17739833.6A patent/EP3481820B1/en active Active
- 2017-07-06 MA MA045588A patent/MA45588A/fr unknown
- 2017-07-06 CN CN201780048867.6A patent/CN109563087A/zh active Pending
- 2017-07-06 BR BR112019000293-6A patent/BR112019000293A2/pt not_active Application Discontinuation
- 2017-07-06 IL IL263996A patent/IL263996B2/en unknown
- 2017-07-06 AU AU2017292818A patent/AU2017292818B2/en active Active
- 2017-07-06 MX MX2019000115A patent/MX389964B/es unknown
- 2017-07-06 JP JP2019500453A patent/JP2019524710A/ja active Pending
- 2017-07-06 WO PCT/US2017/040827 patent/WO2018009609A1/en not_active Ceased
- 2017-07-06 KR KR1020197003464A patent/KR20190025989A/ko not_active Ceased
- 2017-07-07 TW TW106122962A patent/TWI774683B/zh not_active IP Right Cessation
-
2018
- 2018-12-24 JO JOP/2018/0127A patent/JOP20180127A1/ar unknown
-
2019
- 2019-01-04 CL CL2019000018A patent/CL2019000018A1/es unknown
- 2019-01-07 MX MX2022001565A patent/MX2022001565A/es unknown
-
2020
- 2020-12-29 US US17/136,473 patent/US11572358B2/en active Active
-
2022
- 2022-07-04 JP JP2022107994A patent/JP2022130689A/ja active Pending
-
2023
- 2023-06-02 US US18/204,997 patent/US20240059683A1/en not_active Abandoned
- 2023-11-02 US US18/500,565 patent/US20240246947A1/en not_active Abandoned
-
2024
- 2024-08-28 US US18/818,111 patent/US20250129060A1/en not_active Abandoned
-
2025
- 2025-01-10 US US19/016,255 patent/US20250282769A1/en active Pending
- 2025-04-30 JP JP2025075532A patent/JP2025118738A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524710A5 (OSRAM) | ||
| JP2016540017A5 (OSRAM) | ||
| JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
| CA2624310C (en) | Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide | |
| JP2019525915A5 (OSRAM) | ||
| CN102256984B (zh) | 制备二胺衍生物的方法 | |
| JP2013532162A5 (ja) | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用 | |
| HRP20200276T1 (hr) | Stimulatori sgc | |
| WO2019007418A1 (zh) | Fxr受体激动剂 | |
| TWI272263B (en) | PGD2/TXA2 two receptors antagonistic pharmaceutical composition having [2,2,1] and [3,1,1] bicyclo skeleton | |
| JP7683930B2 (ja) | セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用 | |
| JP2015526411A (ja) | 窒素複素環誘導体及びその医薬品への応用 | |
| JP2013533250A5 (ja) | 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用 | |
| WO2016150255A1 (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| CN106432229A (zh) | 一类用于治疗或预防高尿酸血症或痛风的化合物 | |
| TWI861165B (zh) | 新穎嗒 | |
| JP6446051B2 (ja) | １−（３−メチル−２−オキソ−２，３−ジヒドロ−１，３−ベンゾキサゾール−６−イル）−２，４−ジオキソ−３−［（１ｒ）−４−（トリフルオルメチル）−２，３−ジヒドロ−１ｈ−インデン−１−イル］−１，２，３，４−テトラヒドロピリミジン−５−カルボン酸の塩 | |
| EP3759095A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| CN104072481B (zh) | 一种抗血管新生化合物 | |
| WO2018183795A1 (en) | Method of making tetrahydronaphthyridinyl nonanoic acid compounds | |
| JP2004504390A (ja) | （ｒ）−ｎ−［５−メチル−８−（４−メチルピペラジン−１−イル）−１，２，３，４−テトラヒドロ−２−ナフチル］−４−モルホリノベンズアミドの新規な形態 | |
| CN115551846B (zh) | 1,4,5,6-四氢嘧啶-2-胺衍生物 | |
| CN104364255A (zh) | 取代的黄嘌呤衍生物 | |
| CN105753870B (zh) | 一种西地那非杂质f及其制备方法和应用 | |
| CN118339149A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 |